|
1
|
Bartczak-Tomczyk M, Sałagacka A, Mirowski
M, Jeleń A and Balcerczak E: Quantitative analysis of FJ 194940.1
gene expression in colon cancer and its association with
clinicopathological parameters. Contemp Oncol (Pozn). 17:45–50.
2013.PubMed/NCBI
|
|
2
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gulbake A, Jain A, Jain A, Jain A and Jain
SK: Insight to drug delivery aspects for colorectal cancer. World J
Gastroenterol. 22:582–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y,
Cuevas B, Kuo WL, Gray JW, Siciliano M, et al: NOEY2 (ARHI), an
imprinted putative tumor suppressor gene in ovarian and breast
carcinomas. Proc Natl Acad Sci USA. 96:214–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo RZ, Fang X, Marquez R, Liu SY, Mills
GB, Liao WS, Yu Y and Bast RC: ARHI is a Ras-related small
G-protein with a novel N-terminal extension that inhibits growth of
ovarian and breast cancers. Oncogene. 22:2897–2909. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Shi S, Yang W and Chen C:
Over-expression of ARHI decreases tumor growth, migration, and
invasion in human glioma. Med Oncol. 31:8462014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu X, Liang L, Dong L, Yu Z and Fu X:
Effect of ARHI on lung cancer cell proliferation, apoptosis and
invasion in vitro. Mol Biol Rep. 40:2671–2678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bao JJ, Le XF, Wang RY, Yuan J, Wang L,
Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y and Bast RC Jr:
Reexpression of the tumor suppressor gene ARHI induces apoptosis in
ovarian and breast cancer cells through a caspase-independent
calpain-dependent pathway. Cancer Res. 62:7264–7272.
2002.PubMed/NCBI
|
|
10
|
Tang HL, Hu YQ, Qin XP, Jazag A, Yang H,
Yang YX, Yang XN, Liu JJ, Chen JM, Guleng B and Ren JL: Aplasia ras
homolog member I is downregulated in gastric cancer and silencing
its expression promotes cell growth in vitro. J Gastroenterol
Hepatol. 27:1395–1404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, Chen L, Tang Q, Fan Y, Zhang X and
Zhai J: Loss of ARHI expression in colon cancer and its clinical
significance. Contemp Oncol (Pozn). 18:329–333. 2014.PubMed/NCBI
|
|
12
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brabletz T, Hlubek F, Spaderna S,
Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and
metastasis in colorectal cancer: Epithelial-mesenchymal transition,
mesenchymal-epithelial transition, stem cells and beta-catenin.
Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang B, Tang F, Wang Z, Qi G, Liang X, Li
B, Yuan S, Liu J, Yu S and He S: Overexpression of CTNND1 in
hepatocellular carcinoma promotes carcinous characters through
activation of Wnt/β-catenin signaling. J Exp Clin Cancer Res.
35:822016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi L, Sun B, Liu Z, Cheng R, Li Y and Zhao
X: Wnt3a expression is associated with epithelial-mesenchymal
transition and promotes colon cancer progression. J Exp Clin Cancer
Res. 33:1072014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y,
Cuevas B, Kuo WL, Gray JW, Siciliano M, et al: NOEY2 (ARHI), an
imprinted putative tumor suppressor gene in ovarian and breast
carcinomas. Proc Natl Acad Sci USA. 96:214–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Liu M, Zhang Y, Han C, You J, Yang
J, Cao C and Jiao S: Effects of ARHI on breast cancer cell
biological behavior regulated by microRNA-221. Tumour Biol.
34:3545–3554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson
EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, et al:
Transcriptional and posttranscriptional down-regulation of the
imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.
Clin Cancer Res. 12:2404–2413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu J, Kong CZ, Zhang Z, Zhan B and Jiang
ZM: Aplasia Ras homolog member I expression induces apoptosis in
renal cancer cells via the β-catenin signaling pathway. Mol Med
Rep. 11:475–481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krakhmal NV, Zavyalova MV, Denisov EV,
Vtorushin SV and Perelmuter VM: Cancer invasion: Patterns and
mechanisms. Acta Naturae. 7:17–28. 2015.PubMed/NCBI
|
|
23
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Drasin DJ, Robin TP and Ford HL: Breast
cancer epithelial-to-mesenchymal transition: Examining the
functional consequences of plasticity. Breast Cancer Res.
13:2262011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bates RC and Mercurio AM: The
epithelial-mesenchymal transition (EMT) and colorectal cancer
progression. Cancer Biol Ther. 4:365–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Prieto-García E, Díaz-García CV,
García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal
transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mendez MG, Kojima S and Goldman RD:
Vimentin induces changes incell shape, motility, and adhesion
during the epithelial to mesenchymal transition. FASEB J.
24:1838–1851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Liu G, Kang Y, Dong Z, Qian Q and
Ma X: N-cadherin expression is associated with acquisition of EMT
phenotype and with enhanced invasion in erlotinib-resistant lung
cancer cell lines. PLoS One. 8:e576922013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Ji L, Chen J, Zhang W and Ye Z:
Wnt/β-Catenin signaling pathway in skin carcinogenesis and therapy.
Biomed Res Int. 2015:9648422015.PubMed/NCBI
|
|
31
|
Sokol SY: Spatial and temporal aspects of
Wnt signaling and planar cell polarity during vertebrate embryonic
development. Semin Cell Dev Biol. 42:78–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sebio A, Kahn M and Lenz HJ: The potential
of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther
Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Holland JD, Klaus A, Garratt AN and
Birchmeier W: Wnt signaling in stem and cancer stem cells. Curr
Opin Cell Biol. 25:254–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tanaka SS, Kojima Y, Yamaguchi YL,
Nishinakamura R and Tam PP: Impact of WNT signaling on tissue
lineage differentiation in the early mouse embryo. Dev Growth
Differ. 53:843–856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shan S, Lv Q, Zhao Y, Liu C, Sun Y, Xi K,
Xiao J and Li C: Wnt/β-catenin pathway is required for epithelial
to mesenchymal transition in CXCL12 over expressed breast cancer
cells. Int J Clin Exp Pathol. 8:12357–12367. 2015.PubMed/NCBI
|
|
36
|
Ghahhari NM and Babashah S: Interplay
between microRNAs and WNT/β-catenin signalling pathway regulates
epithelial-mesenchymal transition in cancer. Eur J Cancer.
51:1638–1649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li H, Wang Z, Zhang W, Qian K, Liao G, Xu
W and Zhang S: VGLL4 inhibits EMT in part through suppressing
Wnt/β-catenin signaling pathway in gastric cancer. Med Oncol.
32:832015. View Article : Google Scholar : PubMed/NCBI
|
